Cargando…
A Novel Bispecific Antibody Targeting CD3 and Lewis Y with Potent Therapeutic Efficacy against Gastric Cancer
Lewis Y antigen, a glycan highly expressed on most epithelial cancers, was targeted for cancer treatment but lacked satisfactory results in some intractable and refractory cancers. Thus, it is highly desirable to develop an effective therapy against these cancers, hopefully based on this target. In...
Autores principales: | Chen, Jie, Pan, Zhidi, Han, Lei, Zhou, Yuexian, Zong, Huifang, Wang, Lei, Sun, Rui, Jiang, Hua, Xie, Yueqing, Yuan, Yunsheng, Wu, Mingyuan, Bian, Yanling, Zhang, Baohong, Zhu, Jianwei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393954/ https://www.ncbi.nlm.nih.gov/pubmed/34440263 http://dx.doi.org/10.3390/biomedicines9081059 |
Ejemplares similares
-
A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
por: Sun, Rui, et al.
Publicado: (2021) -
Characterization of a novel bispecific antibody targeting tissue factor-positive tumors with T cell engagement
por: Pan, Zhidi, et al.
Publicado: (2022) -
A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer
por: Zhou, Yuexian, et al.
Publicado: (2020) -
Binding domain on CD22 molecules contributing to the biological activity of T cell-engaging bispecific antibodies
por: Chen, Jie, et al.
Publicado: (2023) -
IgG-like Bispecific Antibody CD3×EpCAM Generated by Split Intein Against Colorectal Cancer
por: Wang, Lei, et al.
Publicado: (2022)